Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 802-809

  Li, Rui ^a   Bi, Yi An ^a   Lai, Yurong ^b   Sugano, Kiyohiko ^c   Steyn, Stefanus J ^a   Trapa, Patrick E ^a   Di, Li ^a  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

ADME; hepatocytes; Log D; MDCKII LE; passive permeability

Indexed keywords

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CLEARANCE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPOPHILICITY; LIVER CELL; MDCK CELL LINE; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; MONOLAYER TRANSPORT ASSAY; NONHUMAN; PASSIVE PERMEABILITY; RAT; ACTIVE TRANSPORT; ALGORITHM; ANIMAL; CELL LINE; DOG; METABOLISM; PHYSIOLOGY; SPECIES DIFFERENCE;

ALGORITHMS; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; HEPATOCYTES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; RATS; SPECIES SPECIFICITY;

EID: 84903598993     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9616-5     Document Type: Article

References (24)

1. Yamazaki M, Suzuki H, Sugiyama Y. Recent advances in carriermediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res. 1996;13(4):497-513. doi:10.1023/A:1016077517241. (Pubitemid 26119682)
2. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425-46. doi:10.1016/j.ejps.2005.12.003. (Pubitemid 43363338)
3. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn. 2010;37(6):575-90. doi:10.1007/s10928-010-9176-y.
4. Di L, Keefer C, Scott Dennis O, Strelevitz Timothy J, Chang G, Bi Y-A, et al. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem. 2012;57:441-8. doi:10.1016/j.ejmech.2012.06.043.
5. Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011;54(14):5082-96. doi:10.1021/jm200319u.
6. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, et al. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H- imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem. 2012;55(3):1318-33. doi:10.1021/jm2014887.
7. Tu M, Mathiowetz AM, Pfefferkorn JA, Cameron KO, Dow RL, Litchfield J, et al. Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Top Med Chem (Sharjah, United Arab Emirates). 2013;13(7):857-66. doi:10.2174/1568026611313070008.
8. Poirier A, Cascais A-C, Funk C, Lavé T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009;36(6):585-611. doi:10.1007/s10928-009- 9139-3.
9. Kimoto E, Chupka J, Xiao Y, Bi Y-A, Duignan DB. Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos. 2011;39(1):47-53. doi:10.1124/dmd.110.034298.
10. Menochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 2012;341(1):2-15. doi:10.1124/jpet.111.187112.
11. Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos. 2011;39(10):1808-14. doi:10.1124/dmd.111.040477.
12. Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40(9):1744-56. doi:10.1124/dmd.112.046193.
13. Nordell P, Winiwarter S, Hilgendorf C. Resolving the distribution- metabolism interplay of eight OATP substrates in the standard clearance assay with suspended human cryopreserved hepatocytes. Mol Pharmaceutics. 2013;10(12):4443-51. doi:10.1021/mp400253f.
14. Jones HM, Barton HA, Lai Y, Bi Y-A, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007-17. doi:10.1124/dmd.111.042994.
15. Linder CD, Renaud NA, Hutzler JM. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009;37(1):10-3. doi:10.1124/dmd.108.024075.
16. Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab Dispos. 2011;39(9):1674-9. doi:10.1124/dmd.111.039834.
17. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, et al. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci. 2011;100(11):4974-85. doi:10.1002/jps.22674.
18. a to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists. Drug Metab Dispos. 2009;37(9):1864-70.
19. Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. London: Elsevier; 2008.
20. Ghosh A, Scott DO, Maurer TS. Towards a unified model of passive drug permeation I: origins of the unstirred water layer with applications to ionic permeation. Eur J Pharm Sci. 2014;52:109-24. doi:10.1016/j.ejps.2013.10.004.
21. Saito S, Murakami Y, Miyauchi S, Kamo N. Measurement of plasma membrane potential in isolated rat hepatocytes using the lipophilic cation, tetraphenylphosphonium: correction of probe intracellular binding and mitochondrial accumulation. Biochim Biophys Acta Biomembr. 1992;1111(2):221-30. doi:10.1016/0005-2736(92)90314-C.
22. +. J Gen Physiol. 1998;111(6):825-46.
23. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2009;5(3):259-93. doi:10.1517/17425250902835506.
24. Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos: Biol Fate Chem. 2013;41(4):897-905. doi:10.1124/dmd.112.050054.